Skip to main content

Table 5 Univariable and multivariable cox analysis of DFS after propensity matched analysis

From: Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis

Variable Univariable Multivariable
HR 95% CI P HR 95% CI P
Age (≥60/< 60, year) 1.198 0.587–2.443 0.620
Sex (Men/Women) 1.827 0.713–4.685 0.209
HBsAg (yes/no) 1.478 0.706–3.096 0.300
HCV antibody (yes/no) 0.048 0.526–4.934 0.665
AFP (≥20/< 20, ng/mL) 1.075 0.585–1.976 0.815
CEA (≥5/<5, ng/mL) 0.820 0.380–1.771 0.614
CA19–9 (≥37/<37, U/mL) 1.019 0.520–1.997 0.957
Liver cirrhosis, yes (%) 1.436 0.752–2.744 0.273
TB (≥17/< 17, μmol/L) 0.941 0.449–1.973 0.873
ALB (≥40/<40, g/mL) 0.580 0.315–1.068 0.080
ALT (≥35/<35, U/L) 2.083 1.120–3.873 0.020 1.989 0.980–4.037 0.057
γ-GT (≥40/<40, U/L) 1.265 0.616–2.597 0.521
PLT (≥10/< 10 103/μL) 0.975 0.466–2.043 0.947
Prothrombin time, median (range), s 1.841 0.942–3.598 0.074
Tumour size, cm 1.077 0.560–2.071 0.823
Tumour nodularities 0.992 0.731–1.346 0.957
Occlusion, min (< 20/≥20) 3.308 1.388–6.647 0.005 1.565 0.639–3.833 0.327
Macrovascular invasion (yes/no) 3.703 1.607–8.535 0.002 3.361 1.416–7.977 0.006
Microvascular invasion (yes/no) 1.705 0.854–3.407 0.131
Lymphoid metastasis (yes/no) 1.423 0.553–3.663 0.464
Extrahepatic metastasis (yes/no) 2.246 0.520–9.712 0.279
Preventive TACE (yes/no) 3.144 1.610–6.137 0.001 3.345 1.686–6.638 0.001
  1. HBsAg hepatitis B surface antigen, HCV hepatitis C virus, AFP α-fetoprotein, CEA carcino-embryonic antigen, CA19–9 carbohydrate 19–9, TB total bilirubin, ALB albumin, ALT alanine aminotransferase, γ-GT γ-glutamyl transpeptidase, PLT platelet, ALP alkaline phosphatase, NS non-sense
\